TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
▌TickerSpark Feed

GKOS coverage

Every article, report, and earnings note where GKOS appears.

Glaukos Corporation (GKOS) jumps on record Q3 results
Trending StockGKOS

Glaukos Corporation (GKOS) jumps on record Q3 results

Glaukos Corporation (GKOS) jumps after reporting record third-quarter sales, raising 2026 guidance and unveiling a preliminary $1 billion 2027 sales target. The stronger growth outlook, margin expansion and analyst target hikes helped push the stock above its prior close and 52-week high in after-hours trading.

Oct 29, 2026·5 MIN
Glaukos (GKOS): Growth Surge Meets Premium Valuation
Research ReportGKOS

Glaukos (GKOS): Growth Surge Meets Premium Valuation

Glaukos is scaling rapidly on iDose TR and Epioxa, with Q3 revenue up 58% and 2027 sales guidance topping $1.0B. The stock still screens as a Hold because premium valuation and ongoing losses leave limited margin for error.

Oct 28, 2026·20 MIN
HealthcareMedical DevicesGrowth
Glaukos Corporation (GKOS) Jumps 18.5% on Q3 Beat
Trending StockGKOS

Glaukos Corporation (GKOS) Jumps 18.5% on Q3 Beat

Glaukos Corporation (GKOS) jumps after a strong third-quarter report featuring record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance. The move reflects renewed investor confidence in the company’s ophthalmology platform, though the stock now trades near the top of analyst expectations.

Oct 28, 2026·5 MIN
▌On-Demand Research

Want a deeper dive on GKOS?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate GKOS Report
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌Today's Top MoverGPN
▲9.95%
Global Payments Inc. · $91.83

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA